文献速递白血病造血干细胞移植与细胞治疗

CD8+ T细胞克隆扩增反映移植物抗白血病活性并预测DLI后持久缓解

Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI.
PubMed 文献 · Blood Adv · 2021-01-01

这项前瞻性临床研究对29例接受供者淋巴细胞输注(DLI)的患者进行CD8+ αβ T细胞的深度TCRβ测序,追踪其克隆动态。研究发现,DLI后出现移植物抗白血病(GVL)迹象时,特定CD8+TRB克隆优先扩增(n=14),而无GVL迹象者(n=11)未见此现象。DLI后15天的早期克隆变化可预测36个月随访期间的持久缓解;克隆未扩增则提前中位11.2个月预测复发。

要点

  • DLI后CD8+TRB克隆扩增与GVL活性相关,无GVL者无此扩增。
  • DLI后15天克隆变化可预测持久缓解及复发风险。

核心结论

  • CD8+TRB分析可能成为预测DLI疗效的可靠工具,并有助于识别DLI后进展和复发风险患者。

研究设计与样本

  • 前瞻性临床研究,纳入29例接受DLI的患者,对分选CD8+ αβ T细胞进行深度TCRβ测序以追踪克隆动态。

主要发现

  • 首次出现GVL时,纵向分析显示特定CD8+TRB克隆优先扩增(n=14),而无GVL迹象患者(n=11)样本中未出现此现象。
  • DLI后15天的早期克隆变化预测了36个月研究随访期间的持久缓解。
  • DLI后CD8+TRB克隆未扩增是早期生物标志物,可提前中位11.2个月预测复发。

临床怎么用

  • DLI后可通过CD8+TRB测序监测克隆扩增,早期识别GVL活性及复发风险,辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Donor lymphocyte infusion (DLI) is a standard of care for relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Currently it is poorly understood how and when CD8+ αβ T cells exert graft-versus-leukemia (GVL) activity after DLI. Also, there is no reliable biomarker to monitor GVL activity of the infused CD8+ T cells. Therefore, we analyzed the dynamics of CD8+ αβ T-cell clones in patients with DLI. In this prospective clinical study of 29 patients, we performed deep T-cell receptor β (TRB ) sequencing of sorted CD8+ αβ T cells to track patients' repertoire changes in response to DLI. Upon first occurrence of GVL, longitudinal analyses revealed a preferential expansion of distinct CD8+TRB clones (n = 14). This did not occur in samples of patients without signs of GVL (n = 11). Importantly, early repertoire changes 15 days after DLI predicted durable remission for the 36-month study follow-up. Furthermore, absence of clonal outgrowth of the CD8+TRB repertoire after DLI was an early biomarker that predicted relapse at a median time of 11.2 months ahead of actual diagnosis. Additionally, unbiased sample analysis regardless of the clinical outcome revealed that patients with decreasing CD8+TRB diversity at day 15 after DLI (n = 13) had a lower relapse incidence (P = .0040) compared with patients without clonal expansion (n = 6). In conclusion, CD8+TRB analysis may provide a reliable tool for predicting the efficacy of DLI and holds the potential to identify patients at risk for progression and relapse after DLI.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schultze-Florey CR, Kuhlmann L, Raha S, et al. Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI. Blood Adv. 2021. PMID: 34535011. doi:10.1182/bloodadvances.2020004073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。